Novo Nordisk A/S Class B NONOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NONOF is a good fit for your portfolio.
News
-
Eight stock picks in AI, obesity drugs, -2-
-
Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500
-
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
-
This weight-loss ETF has performed well in its -2-
-
Ozempic, similar weight-loss drugs don't increase suicide risk: EU regulator
-
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says
-
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
-
Wegovy's heart benefits are not just linked with weight loss, new study suggests
Trading Information
- Previous Close Price
- $124.15
- Day Range
- $122.80–125.22
- 52-Week Range
- $74.70–140.32
- Bid/Ask
- $120.38 / $126.03
- Market Cap
- $547.90 Bil
- Volume/Avg
- 4,392 / 39,127
Key Statistics
- Price/Earnings (Normalized)
- 45.44
- Price/Sales
- 16.37
- Dividend Yield (Trailing)
- 1.10%
- Dividend Yield (Forward)
- 0.22%
- Total Yield
- 1.89%
Company Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 60,000
- Website
- https://www.novonordisk.com
Competitors
Valuation
|
Metric
|
NONOF
|
SNY
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 45.44 | 9.64 | 89.00 |
Price/Book Value | 34.59 | 1.50 | 65.81 |
Price/Sales | 16.37 | 2.29 | 19.77 |
Price/Cash Flow | 31.38 | 11.20 | 92.46 |
Price/Earnings
NONOF
SNY
LLY
Financial Strength
|
Metric
|
NONOF
|
SNY
|
LLY
|
|---|---|---|---|
Quick Ratio | 0.62 | 0.83 | 0.52 |
Current Ratio | 0.82 | 1.27 | 0.94 |
Interest Coverage | 192.15 | 11.03 | 14.13 |
Quick Ratio
NONOF
SNY
LLY
Profitability
|
Metric
|
NONOF
|
SNY
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | 30.82% | 8.05% | 10.22% |
Return on Equity (Normalized) | 94.27% | 14.38% | 52.03% |
Return on Invested Capital (Normalized) | 72.84% | 10.85% | 19.27% |
Return on Assets
NONOF
SNY
LLY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qzmjmhkzxz | Pkjc | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wdcshzq | Yzcyg | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pzlgphfp | Sfwxn | $98.9 Bil | |
MRNA
| Moderna Inc | Vnxlybrcd | Sspn | $39.7 Bil | |
ARGX
| argenx SE ADR | Cyxqrwnj | Nbfz | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Vjxxgzmy | Tjgg | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xdqsbygcw | Wklhct | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xsbchhft | Mlxqyy | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jxvrztnbs | Kyygzc | $12.3 Bil | |
INCY
| Incyte Corp | Mjxfzvx | Rtgwqq | $11.8 Bil |